Medtronic product performs well during trial

Medtronic has highlighted the results of a study which showed that the product brings about improved glycemic control in paediatric patients who have been newly diagnosed with type 1 diabetes using the MiniMed Paradigm Real-Time System.

The trial, which was conducted in Austria, France, Germany, and Poland, indicated that using personal continuous glucose monitoring (CGM) on a regular basis improves glycemic control.

During the study, the MiniMed Paradigm Real-Time System was compared to a control group using a conventional insulin pump with self monitoring of blood glucose.

“It is quite evident that children with type 1 diabetes can benefit from using insulin pump therapy with real-time continuous glucose monitoring at the onset of their disease,” explained Thomas Danne, lead investigator and chief physician at the diabetes centre for children and adolescents in Hanover, Germany.

Medtronic also announced this month that it has entered into a partnership with PEAK Surgical for the marketing and distribution of the PEAK PlasmaBlade TnA Tonsil and Adenoid tissue dissection device.